Hemorrhagic Fever, Ebola
Conditions
Keywords
Ebola virus, Filoviridae Infections, Hemorrhagic Fever, Ebola, Viral Diseases, Hemorrhagic Fevers, Viral
Brief summary
Phase Ib study in 90 healthy adults,18 years to 65 years of age, to evaluate the safety, tolerability and immunogenicity of the VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ) investigational Ebola vaccines in Part 1 and boosting with the VRC-EBOMVA079-00-VP (MVA-EbolaZ) investigational Ebola vaccine in Part 2. Part 1: Randomizations to cAd3-EBO or cAd3-EBOZ at two different dose levels within Group 1 will include at least 60 volunteers who have never received an investigational Ebola vaccine. Randomizations to cAd3-EBO at two different dose levels within Group 2 may include up to 30 eligible participants who previously participated in the RV247 vaccine clinical trial and received the investigational VRC-EBODNA023-00-VP (Ebola DNA WT) vaccine. Part 2: Participants in Part 1 may receive a booster vaccination with the MVA-EbolaZ vaccine at the same dose level.
Detailed description
Study Design: This Phase 1b, open-label study to examine safety, tolerability and immunogenicity of investigational Ebola vaccines is conducted in two Parts. In Part 1 subjects are randomized to receive either the cAd3-EBO or cAd3-EBOZ vaccine at two different dose levels. In Part 2, participants from Part 1 may receive a booster injection with the MVA-EbolaZ vaccine; all at the same dose level. The hypotheses are that the study vaccines, cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ, will be safe and will elicit immune responses to Ebola glycoprotein (GP). The primary objectives are to evaluate the safety and tolerability of the study vaccines administered as intramuscular (IM) injections. The secondary objectives are related to immunogenicity. Study Products Description: VRC-EBOADC069-00-VP (cAd3-EBO) is composed of two recombinant cAd3 vectors in a 1:1 ratio that express Ebola WT GPs from Zaire and Sudan strains. It is formulated at 2x10(11) particle units (PU)/mL. VRC-EBOADC076-00-VP (cAd3-EBOZ) is composed of a cAd3 vector that expresses Ebola WT GP from the Zaire strain. It is formulated at 1x10(11) PU/mL. VRC-DILADC065-00-VP (diluent) is the vaccine formulation buffer and will be used when needed to prepare the correct dosage of cAd3-EBO or cAd3-EBOZ. VRC-EBOMVA079-00-VP (MVA-EbolaZ) is composed of a MVA vector that expresses Ebola WT GP from the Zaire strain. It is formulated at 3.2x10(8) PFU/mL. Part 1 Study Plan: Group 1: 60 volunteers will be randomized: 15 in each of the two dosage groups for VRC-EBOADC069-00-VP \[2x10(10) PU or 2x10(11) PU\] and 15 in each of the two dosage groups for VRC-EBOADC076-00-VP \[1x10(10) PU or 1x10(11) PU\]. Group 2: up to 30 volunteers that previously participated in the RV 247 clinical trial who received the investigational product VRC-EBODNA023-00-VP will be randomized to receive one of the two dosage groups for VRC-EBOADC069-00-VP. The two groups will be enrolled simultaneously. If less then 30 participants enroll into Group 2, additional participants may be enrolled into Group 1 for a total of 90 participants overall. Participants will be evaluated by 9 clinic visits over 48 weeks. Part 2 Study Plan: Part 1 participants who received a study vaccination and have completed at least 36 weeks of follow-up, who are eligible and consent may receive a booster injection with the VRC-EBOMVA079-00-VP vaccine at 1x10(8) particle forming units (PFU). Participants will be evaluated by 11 clinic visits over 48 weeks after beginning Part 2.
Interventions
BIOLOGICALMVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
BIOLOGICALcAd3-EBOZ
cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
BIOLOGICALcAd3-EBO
1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
Sponsors
US Military HIV Research Program
The Emmes Company, LLC
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Part 1 Inclusion Criteria: A volunteer subject must meet all of the following criteria: * 18 to 65 years old. * Available for clinical follow-up through Week 48. * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. * Must be willing to be taken home at enrollment visit and allow home visits if participant does not keep appointments * Must complete an Assessment of Understanding successfully. * Able to read (English or Luganda) and willing to complete the informed consent process. * Willing to donate blood for sample storage to be used for future research. * In good general health without clinically significant medical history. * Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) ≤ 40 within the 56 days prior to enrollment. Laboratory Inclusion Criteria within 56 days prior to enrollment: * Hemoglobin ≥ 11.0 g/dL for women; ≥12.5 g/dL for men. * White blood cells (WBC) = 2,500-12,000 cells/mm3. * WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval. * Total lymphocyte count ≥ 800 cells/mm3. * Platelets = 125,000 - 400,000/mm3. * Alanine aminotransferase (ALT) ≤ 1.25 x upper limit of normal (ULN). * Serum creatinine ≤ 1 x ULN. * Partial thromboplastin time (PTT) within institutional normal range. * Prothrombin time (PT) within institutional normal range. * HIV-uninfected as evidenced by a negative FDA-approved HIV diagnostic test. Female-Specific Inclusion Criteria: * Negative β-HCG (human chorionic gonadotropin) pregnancy test on day of enrollment. * Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if presumed to be of reproductive potential. Part 1
Exclusion criteria
Volunteer has received any of the following substances: * Investigational Ebola or Marburg vaccine (other than the Ebola DNA vaccine delivered in RV 247) in a prior clinical trial or prior receipt of a cAd3 adenoviral vectored investigational vaccine. * Chronic use of immunomodulators and systemic glucocorticoids in daily doses of glucocorticoid equivalence \> 20 mg of prednisolone, for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs \[NSAIDS\] are permitted. * Participants that have used less than the stated glucocorticoid dose may still be excluded at the Investigator's discretion. * Blood products within 112 days prior to enrollment. * Investigational research agents within 28 days prior to enrollment. * Live attenuated vaccines within 28 days prior to enrollment. * Subunit or killed vaccines within 14 days prior to enrollment. * Current anti-tuberculosis prophylaxis or therapy. Female-Specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of solicited adverse events after vaccination | 7 days | Incidence is reported for solicited events for 7 days after each vaccination. |
| Incidence of unsolicited adverse events of any severity 28 days after vaccination | 28 days | Incidence is reported for unsolicited events for 28 days after each vaccination. The reporting period is Day 0 to Day 28. |
| Incidence of serious adverse events or new chronic medical conditions through the last study visit | From first study injection through 48 weeks after final study injection | Incidence is reported of serious adverse events and new chronic medical conditions for 48 weeks after vaccination. |
| Mean change from baseline in safety laboratory measures | 28 days after each vaccination | At Days 2 or 3, 14, and 28 blood will be drawn to measure safety measures that many include complete blood count (CBC), creatinine, ALT, PT and PTT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antibody response to Ebola GP as measured by neutralization assay | 4 weeks after vaccination | Blood is collected at baseline and 4 weeks after vaccination |
| T cell immune response measured by intracellular cytokine staining (ICS) | 4 weeks after vaccination | Blood is collected at baseline and 4 weeks after vaccination |
| Antibody response to Ebola GP as measured by ELISA | 4 weeks after each vaccination | Blood is collected at baseline and 4 weeks after vaccination |
Countries
Uganda
Outcome results
None listed